Bone scintigraphy in evaluating the viability of composite bone grafts revascularized by microvascular anastomoses, conventional autogenous bone grafts, and free non-revascularized periosteal grafts.
We studied the value of bone scintigraphy in the assessment of anastomotic patency and bone-cell viability in free bone grafts revascularized by microvascular anastomoses in twenty-seven dogs. The dogs were divided into three different groups, and scintigraphy was carried out using technetium-labeled methylene diphosphonate in composite bone grafts revascularized by microvascular anastomoses, conventional autogenous bone grafts, and periosteal grafts placed in different recipient beds. The viability of the grafts was evaluated by histological examination and fluorescence microscopy after triple labeling with oxytetracycline on the first postoperative day, alizarin complexone on the fourth postoperative day, and DCAF on the eleventh postoperative day. A positive scintiscan within the first week following surgery indicated patent microvascular anastomoses, and histological study and fluorescence microscopy confirmed that bone throughout the graft was viable. A positive scintiscan one week after surgery or later does not necessarily indicate microvascular patency or bone-cell survival, because new bone formed by creeping substitution on the surface of a dead bone graft can result in this finding.
D000818:Animals; D016025:Bone Transplantation; D001842:Bone and Bones / Q000098:blood supply / Q000000981:diagnostic imaging; D004164:Diphosphonates; D004285:Dogs; D006085:Graft Survival; D008833:Microcirculation / Q000000981:diagnostic imaging / Q000601:surgery; D010521:Periosteum / Q000098:blood supply / Q000000981:diagnostic imaging / Q000637:transplantation*; D011877:Radionuclide Imaging; D013667:Technetium; D013669:Technetium Tc 99m Medronate
D004164:Diphosphonates; C023568:technetium Tc 99m (Sn)methylenediphosphonate; D013667:Technetium; D013669:Technetium Tc 99m Medronate